array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2747) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(80) "Nasal Polyposis Drugs Market Research Report 2023-2087 – Bosnian National Team" ["snippet_en"]=> string(262) "According to a recent Factor survey, the global nasal polyposis drug is poised to capture significant market opportunities from a variety of end-use industries. This study of the global Nasal Polyposis Drug market provides a comprehensive analysis of the various" ["url"]=> string(100) "https://bnm.ba/news/marktforschungsbericht-fuer-medikamente-gegen-nasenpolyposis-2023-2087-2/503670/" ["image_url"]=> NULL ["source"]=> string(6) "bnm.ba" ["publication_date"]=> string(10) "2024-11-09" ["categories"]=> array(3) { [0]=> string(19) "New Revenue Streams" [1]=> string(15) "Market Movement" [2]=> string(17) "Academic Research" } } [1]=> array(7) { ["title_en"]=> string(75) "(3⁺) Desired analyzes of stocks in the USA: A firework display of setups!" ["snippet_en"]=> string(131) "What a joy to end the week! You suggested values ​​to me, and sometimes one chart was nicer than the other. Thank you for that!" ["url"]=> string(82) "https://stock3.com/news/wunschanalysen-aktien-usa-ein-feuerwerk-an-setups-15694878" ["image_url"]=> string(78) "https://images.businessradar.com/articles/329af5bd-a24c-4097-afa8-d7f53bf38865" ["source"]=> string(10) "stock3.com" ["publication_date"]=> string(10) "2024-11-09" ["categories"]=> array(0) { } } [2]=> array(7) { ["title_en"]=> string(91) "Sanofi/Regeneron’s Dupixent approved by EC for younger eosinophilic oesophagitis patients" ["snippet_en"]=> string(85) "Dupixent is now the first drug in the EU indicated for use in this patient population" ["url"]=> string(120) "https://pmlive.com/pharma_news/sanofi-regenerons-dupixent-approved-by-ec-for-younger-eosinophilic-oesophagitis-patients/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/241ab0fe-b26c-4ed5-8675-7dfb4d3a5ba5" ["source"]=> string(10) "pmlive.com" ["publication_date"]=> string(10) "2024-11-08" ["categories"]=> array(0) { } } [3]=> array(7) { ["title_en"]=> string(71) "Breakthrough EU approval for Dupixent offers new hope for children with" ["snippet_en"]=> string(193) "The European Medicines Agency (EMA) has granted approval for Dupixent, a therapy developed by Sanofi and Regeneron, to treat eosinophilic esophagitis (EoE) in children as young as one year old." ["url"]=> string(133) "https://www.business-news-today.com/breakthrough-eu-approval-for-dupixent-offers-new-hope-for-children-with-eosinophilic-esophagitis/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/5cdc7c20-e3df-42d3-8a81-d35410199d5e" ["source"]=> string(23) "business-news-today.com" ["publication_date"]=> string(10) "2024-11-08" ["categories"]=> array(0) { } } [4]=> array(7) { ["title_en"]=> string(90) "Sanofi, Regeneron Dupixent approved in EU for young children with eosinophilic esophagitis" ["snippet_en"]=> string(198) "Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year of age. Specifically, the..." ["url"]=> string(145) "https://medicaldialogues.in/news/industry/pharma/sanofi-regeneron-dupixent-approved-in-eu-for-young-children-with-eosinophilic-esophagitis-137671" ["image_url"]=> string(78) "https://images.businessradar.com/articles/1d0b4c34-1336-466d-a9c2-e0ddaf775950" ["source"]=> string(19) "medicaldialogues.in" ["publication_date"]=> string(10) "2024-11-08" ["categories"]=> array(1) { [0]=> string(22) "EU Political Evolution" } } [5]=> array(7) { ["title_en"]=> string(44) "EMA approves Dupixent for young EoE patients" ["snippet_en"]=> string(116) "The EMA has granted approval for Sanofi/Regeneron’s Dupixent (dupilumab) to treat EoE in children as young as one." ["url"]=> string(70) "https://www.pharmaceutical-technology.com/news/ema-dupixent-young-eoe/" ["image_url"]=> NULL ["source"]=> string(29) "pharmaceutical-technology.com" ["publication_date"]=> string(10) "2024-11-07" ["categories"]=> array(0) { } } [6]=> array(7) { ["title_en"]=> string(152) "Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis, by @GlobeNewswire" ["snippet_en"]=> string(205) "Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to one year" ["url"]=> string(85) "https://ceo.ca/@globenewswire/dupixent-dupilumab-approved-in-the-european-union-d5f89" ["image_url"]=> string(78) "https://images.businessradar.com/articles/f56b01d8-3cd8-4480-8a2f-4b3d6d2dc787" ["source"]=> string(6) "ceo.ca" ["publication_date"]=> string(10) "2024-11-06" ["categories"]=> array(1) { [0]=> string(13) "Collaboration" } } [7]=> array(7) { ["title_en"]=> string(97) "Harvest Portfolios Group Inc. Sells 7,046 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(300) "Harvest Portfolios Group Inc. lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 13.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,340 shares of the biopharmaceutical company's sto" ["url"]=> string(144) "https://www.marketbeat.com/instant-alerts/harvest-portfolios-group-inc-sells-7046-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn-2024-11-06/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/dccc8212-3a85-4003-bde6-62fcf8c852ab" ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2024-11-06" ["categories"]=> array(7) { [0]=> string(18) "General Investment" [1]=> string(31) "Financial Update/Profit Warning" [2]=> string(24) "Stock Research & Ratings" [3]=> string(11) "Regulations" [4]=> string(10) "Divestment" [5]=> string(12) "Stock Market" [6]=> string(11) "Acquisition" } } [8]=> array(7) { ["title_en"]=> string(183) "MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting" ["snippet_en"]=> string(120) "Late breaking abstract to provide new updates from THIO-101 Phase 2 clinical trial in non-small cell lung cancer (NSCLC)" ["url"]=> string(221) "https://www.biospace.com/press-releases/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-for-oral-and-poster-presentation-at-the-society-for-immunotherapy-of-cancer-sitc-39th-annual-meeting" ["image_url"]=> string(78) "https://images.businessradar.com/articles/0cd27a8c-aa2c-4aa3-881c-405f1257e339" ["source"]=> string(12) "biospace.com" ["publication_date"]=> string(10) "2024-11-06" ["categories"]=> array(0) { } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(263) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(201) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(196) } [3]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(129) } [4]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(116) } [5]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(116) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(93) } [7]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(79) } [8]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(67) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(66) } [10]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(61) } [11]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(59) } [12]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(57) } [13]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(56) } [14]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(53) } [15]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(43) } [16]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(40) } [17]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(38) } [18]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(37) } [19]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(37) } [20]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(37) } [21]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(35) } [22]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(33) } [23]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(31) } [24]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(31) } [25]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(28) } [26]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(28) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(25) } [28]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(21) } [29]=> array(2) { ["name"]=> string(21) "Intellectual Property" ["count"]=> int(20) } } } c469a-us-regeneron-pharmaceuticals-inc